Search results :

Rapamycin

More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Code: L04AA10

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11
Oedema peripheral 48% - 64% 42% - 48% x x x x x x x x x x x
Hypertension very common, 23% - 49% 41% - 48% x x x x x x x x x x x
Hypertriglyceridaemia postmarketing — 45% - 57% 23% x x x x x x x x
Hypercholesterolaemia postmarketing, 23% - 46% 20% - 23% x x x x x x x x
Creatinine increased postmarketing, 22% - 40% 33% - 38% x x x x x x x x x x
Constipation 28% - 38% 28% - 31% x x x x x x x x x x x
Headache 10% - 34% 20% - 31% x x x x x x x x x x x
Local reaction 34% 34% x
Body temperature increased 19% - 35% 23% - 35% x x x x x x x x x x x
Hyperlipidaemia very common, 23% - 57% 20% - 23% x x x x x x x
Nausea 25% - 39% 22% - 29% x x x x x x x x x x x
Abdominal pain very common, 22% - 36% 23% - 30% x x x x x x x x x x x
Pain 20% - 33% 21% - 25% x x x x x x x x x x x
Asthenia 22% - 40% 19% - 28% x x x x
Diarrhoea 5.1% - 42% 14% - 27% x x x x x x x x x x x
Anaemia very common, 21% - 37% 14% - 21% x x x x x x x x x x x
Urinary tract infection very common, 19.8% - 33% 21.5% - 26% x x x x x x x x x x x
Arthralgia very common, 13% - 31% 15% - 18% x x x x x x x x x x x
Vomiting 19% - 31% 16% - 21% x x x x
Dyspnoea 14% - 30% 23% - 30% x x x x
Dyspepsia 17% - 34% 25% - 34% x x x x
Back pain 16% - 26% 17% - 20% x x x x
Tremor 18% - 31% 11% - 19% x x x x
Acne very common, 11% - 31% 14% - 19% x x x x x x x x x x x
Pyelonephritis postmarketing — 19.8% - 23.1% 21.5% x x x x x x x x x x x
Hypophosphataemia postmarketing, 15% - 23% 19% x x x x x x x x x x x
Chest pain 12% - 24% 16% - 19% x x x x
Oedema 15% - 24% 7% - 15% x x x x x x x x x x x
Hyperkalaemia 12% - 27% 23% - 27% x x x x x x x x x
Pharyngitis 16% - 22% 22% x x x x
Weight increased 8% - 21% 13% - 15% x x x x
Thrombocytopenia 7% - 30% 3% - 9% x x x x x x x x x x x
Insomnia 8% - 22% 8% x x x x
Haematuria 13% 9% x x x x
Upper respiratory tract infection 13% 23% x x
Cough increased 13% 17% x x x x
Leukopenia postmarketing, 8% - 20% 2% - 8% x x x x x x x x x
Dizziness 11% 8% x x x x
Hypokalaemia postmarketing, 9% - 21% 6% - 9% x x x x x x x x x x x
Dysuria 10% 6% x x x x
Rash common, 2% - 20% 5% - 6% x x x x x x x x x x x
Hypotension 10% 6% x x x x
Accidental injury 9% 10% x
Enlargement abdomen 9% 10% x x x x
Rhinitis 8% 8% x x x x
Abnormal vision 8% 6% x x x x
Ecchymosis 7% 3% x x x x
Wound infection 5% - 8.3% 6.9% x
Sepsis postmarketing, 3.7% - 6.7% 6.9% x x x x x x x x x x x
Hypoaesthesia 6% 5% x x x x
Oliguria 6% 10% x x x x
Herpes simplex postmarketing, 3.7% - 12.2% 6.2% x x x x x x x x x
Paraesthesia 4% 6% x x x x
Tachycardia postmarketing — 4% 4% x x x x x x x x x x x
Face oedema 4% 4% x x x x
Transplant rejection 3% 15% x
Hirsutism 3% 8% x x x x
Lymphocele postmarketing — 3% 6% x x x x x x x x x x x
Osteonecrosis postmarketing, common x x x x x x x x x x x
Stomatitis postmarketing, common x x x x x x x x x x x
Cytomegalovirus infection 0.4% - 4.1% 0.8% - 5.4% x
Impaired healing postmarketing — 4% 6% x x x x x x x x x x x
Chills 2% 8% x x x x
Herpes zoster postmarketing, 1.8% - 2.2% 3.1% x x x x x x x x x x x
Carcinoma 0.4% - 8.8% 3.1% x x x x
Melanoma skin 0.4% - 8.8% 3.1% x x x x x x x
Neoplasm malignant postmarketing, 0% - 7% 0% - 2.3% x x x x x x x x x x x
Lymphoproliferative disorder postmarketing, 0.4% - 1.4% 0% - 3.2% x x x x x x x x x x
Lymphoma postmarketing — 0.4% - 1.4% 0% x x x x x x x x x x x
Epistaxis postmarketing — 1% 0% x x x x x x x x x x x
Pancreatitis postmarketing, uncommon x x x x x x x x x x x
Post transplant lymphoproliferative disorder postmarketing, uncommon x x x x x x x x
Amenorrhoea postmarketing x x x x
Angioedema postmarketing x x x x x x x x x
Ascites postmarketing x x x x x x x x
Azoospermia postmarketing x x x x x x x
Basal cell carcinoma postmarketing x x x x x x x
Squamous cell carcinoma postmarketing x x x x x x x
Infection postmarketing x x x x x x x x x x x
Dermatitis exfoliative postmarketing, rare x x x x x x x x x
Effusion postmarketing, uncommon x x x x x x x x
Enterocolitis postmarketing x x x x
Focal segmental glomerulosclerosis postmarketing x x x x x x
Haemolytic uraemic syndrome postmarketing x x x x x x x x x x
Hyperglycaemia postmarketing, 13% 10% x x x x x x x x x x x
Hypersensitivity postmarketing, rare x x x x x x x x x
Nephropathy postmarketing x x x x
Progressive multifocal leukoencephalopathy postmarketing x x x x
Lymphoedema postmarketing, rare x x x x x x x x x
Menorrhagia postmarketing x x x x x x x x
Menstrual disorder postmarketing x x x x
Mycobacterial infection postmarketing x x x x x x x x x x x
Nephrotic syndrome postmarketing, uncommon x x x x x x x x x
Neutropenia postmarketing x x x x x x x
Ovarian cyst postmarketing, common x x x
Pancytopenia postmarketing x x x x x x x x x
Pericardial effusion postmarketing, uncommon x x x x x x x x
Pleural effusion postmarketing x x x x x x x x x x x
Pneumonia postmarketing, 1.2% - 10.3% 3.9% x x x x x x x x x x x
Proteinuria postmarketing x x x x x x x x x
Alveolar proteinosis postmarketing, rare x x x x x x
Pulmonary embolism postmarketing x x x x x x x x x
Pulmonary fibrosis postmarketing x x x x x x x x x x x
Thrombotic thrombocytopenic purpura postmarketing x x x x x x x x x
Tuberculosis postmarketing x x x x x x x x
Deep vein thrombosis postmarketing x x x x x x x x x
Allergic cutaneous angiitis postmarketing x x x x x x x x x
Pulmonary haemorrhage postmarketing x x x x x x x x x
Liver function test abnormal postmarketing — 9% 7% x x x x x x x x x x x
Hepatic necrosis postmarketing x x x x x x x x x x x
Aspartate aminotransferase increased postmarketing x x x x x x x x x x x
Alanine aminotransferase increased postmarketing x x x x x x x x x x x
Unspecified disorder of skin and subcutaneous tissue rare x x
Interstitial lung disease postmarketing x x x x x x x x x x x
Hepatotoxicity postmarketing x x x x x x x x x x
Bronchiolitis obliterans with organizing pneumonia postmarketing x x x x x x x x x
Incisional hernia postmarketing x x x x x x x x
Hepatobiliary disease postmarketing x x x x x x x
Anaphylactoid reaction postmarketing x x x x x x x x x
Cholesterol serum elevated postmarketing x x x x x
Skin carcinoma postmarketing x
Renal graft loss postmarketing x x x
Venous thromboembolism postmarketing x x x x x x x x
Abdominal distension x
Abscess x x x
Acidosis x x x x x
Albuminuria x x x x x
Anorexia x x x x
Anxiety x x x x
Asthma x x x x
Atelectasis x x x x
Atrial fibrillation x x x
Bacterial infection x x x
Benign neoplasm of skin x
Bone disorder x
Breast disorder x x
Obliterative bronchiolitis x x
Bronchitis x x x
Oral candidiasis x x x
Skin cancer x x
Cellulitis x x x
Confusional state x x x x
Conjunctivitis x x x x
Connective tissue disorder x
Cushing's syndrome x x x x
Cyst x
Deafness x x x
Dysphagia x x x x
Dehydration x x x x
Fungal skin infection x x x
Diabetes mellitus x x x x x
Ear pain x x x x
Eructation x x x x
Oesophagitis x x x x
Flatulence x x x x
Gastritis x x x
Gastroenteritis x x x
Gastrointestinal disorder x x
Gingival hyperplasia x x x x x x x x x x
Gingivitis x x x x
Glycosuria x x x x
Gout x x
Hallucination x
Cardiac disorder x x
Cardiomegaly x x
Cardiac failure congestive x x x x
Haemoptysis x
Haemorrhage x x x x
Hernia x x x x
Hiccups x
Hydronephrosis x x x x
Hyperbilirubinaemia x
Hypercalcaemia x x x x
Hypocalcaemia x x x x
Hypoglycaemia x x x x
Hyponatraemia x x x x
Hypoproteinaemia x
Orthostatic hypotension x x x x
Immune system disorder x
Influenza x x x
Arthropathy x x x x x
Cramps of lower extremities x x x x
Leukocytosis x x x x
Mediastinal disorder x x
Malignant melanoma postmarketing — 0% - 1.4% 0% - 1.4% x x x x x x x x
Metrorrhagia x x x x
Hypertonia x x x x
Hypotonia x x x x
Nail disorder x
Neoplasm x
Nervous system disorder x
Nervousness x
Nocturia x x x x
Osteoporosis x x x x
Otitis media x x x
Palpitations x x x x
Parathyroid disorder x
Pelvic pain x x x x
Peritonitis x x x
Polycythaemia x x x x
Polyp x
Polyuria x x x x
Pruritus x x x x
Pulmonary oedema x x x x
Pyuria x x x
Rectal disorder x x
Sinusitis x x x x
Skin disorder x
Skin ulcer x x x x
Sweating x x x x
Syncope x x x
Testicular disorder x x x x
Tetany x x x x
Thrombophlebitis x x x x
Thrombosis x x x x
Tinnitus x x x x
Uremia x
Pollakiuria x x x x
Urinary incontinence x x x x
Urinary tract disorder x x x
Angiopathy x x
Viral infection x
Weight decreased x x x x
Wound x x x x x
Urinary retention x x x x
Peripheral vascular disorder x x x x
Hepatic failure x
Agitation x
Mood swings x x x
Hyperphosphataemia x x x x
Cataract x x x x
Epstein-Barr virus infection x x x
Mouth ulceration x x x x x
Hormone level abnormal x
Arterial anomaly x
Blood urea increased x x x x
Cataract specified x
Creatine phosphokinase increased x x x x
Generalised oedema x x x x
Scrotal oedema x x x x
Skin hypertrophy x x x x
Hypomagnesaemia x x x x
Kidney function abnormal x x x x x x x x
Lactic dehydrogenase activity increased x x x x x
Hepatocellular injury x x
Bone pain x
Circumoral paresthesia x
Phosphatase alkaline increased x x x x
Decreased tolerance x
Malnutrition x x
Fatal outcomes x
Malaise x x x x
Myalgia x x x x
Increased appetite x
Bladder pain x x x x
Blood creatinine increased x
Urine abnormality x
Infection susceptibility increased x x x x x x
Erectile dysfunction x x x x
Organising pneumonia x x
Hepatic artery thrombosis x x x x x
Chronic allograft nephropathy x x x x x x x x
Laboratory test abnormal x
Neuropathy x x x x
Lymphadenopathy x x x
Fluid overload x x x x
Renal pain x x x x
Nephropathy toxic x x x x x x x x x x
Hyperuricaemia x x x x x x x x
Hyperlactacidaemia x
Serum triglycerides increased x x x x x
Infestation NOS x
Blood and lymphatic system disorders x
Blood lactate dehydrogenase increased x
Thrombocytopenic purpura x x
Carcinogenicity x
Graft loss x x x x x x x x
Cyclosporine toxicity x x x x x x x
Ileus x x x x x
Pneumocystis jirovecii pneumonia 0% - 0.4% 0% x
Renal tubular necrosis x x x x
Acute allograft rejection x x x x x x x x
Somnolence x x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

sirolimus / sirolimus

Side effects:99
Source:EMA

SIROLIMUS / RAPAMUNE

Side effects:89
Source:FDA

SIROLIMUS / RAPAMUNE

Side effects:90
Source:FDA

sirolimus

Side effects:92
Source:FDA Structured Product Label

SIROLIMUS

Side effects:102
Source:FDA Structured Product Label

SIROLIMUS

Side effects:102
Source:FDA Structured Product Label

RAPAMUNE (sirolimus) tablets / RAPAMUNE (sirolimus)

Side effects:111
Source:medicines.org.au

SIROLIMUS / RAPAMUNE

Side effects:174
Source:FDA

sirolimus / Rapamune

Side effects:175
Source:FDA

sirolimus / Rapamune

Side effects:196
Source:FDA

SIROLIMUS / RAPAMUNE ORAL SOLUTION

Side effects:227
Source:Health Canada

Color scheme:

standardalternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label